Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers

Objective: Grade 3 endometrioid and uterine serous carcinomas (USC) account for the vast majority of endometrial cancer deaths. The purpose of this study was to determine folic acid receptor alpha (FR⍺) expression in biologically aggressive (type II) endometrial cancers and to evaluate FR⍺ as a targetable receptor for...